Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
Status:
Completed
Trial end date:
2013-12-19
Target enrollment:
Participant gender:
Summary
The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneously
once every 2 weeks (Q2W) and once monthly (QM), compared with placebo, on percent change from
baseline in low-density lipoprotein cholesterol (LDL-C) in adults with heterozygous familial
hypercholesterolemia (HeFH).